These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15551171)

  • 21. Multiple eruptive dermatofibromas in a patient receiving efalizumab.
    Santos-Juanes J; Coto-Segura P; Mallo S; Galache C; Soto J
    Dermatology; 2008; 216(4):363. PubMed ID: 18292655
    [No Abstract]   [Full Text] [Related]  

  • 22. Extended abstracts of the annual meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR), Vienna, Austria, 2005.
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):566-608. PubMed ID: 16625725
    [No Abstract]   [Full Text] [Related]  

  • 23. [Working group of Dermatologic Oncology ADO. Second-line therapy in stage IV melanoma].
    J Dtsch Dermatol Ges; 2007 Oct; 5(10):959. PubMed ID: 17910683
    [No Abstract]   [Full Text] [Related]  

  • 24. Pushing the limits: developing a new standard of care for psoriasis.
    Weinberg JM
    Cutis; 2018 Mar; 101(3S):4. PubMed ID: 29718026
    [No Abstract]   [Full Text] [Related]  

  • 25. [Ustekinumab].
    Ortonne JP
    Ann Dermatol Venereol; 2011 Dec; 138(12):848-50. PubMed ID: 22137626
    [No Abstract]   [Full Text] [Related]  

  • 26. Cepharanthine: a therapeutic potential candidate for psoriasis.
    Pazyar N; Jamshydian N
    J Altern Complement Med; 2012 Jul; 18(7):639-40. PubMed ID: 22747436
    [No Abstract]   [Full Text] [Related]  

  • 27. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100.
    Manalo IF; Gilbert KE; Wu JJ
    J Drugs Dermatol; 2015 Oct; 14(10):1086-8. PubMed ID: 26461817
    [No Abstract]   [Full Text] [Related]  

  • 28. Psoriasis: targeting therapy towards the inflammatory cascade.
    Miteva M
    Am J Clin Dermatol; 2010; 11 Suppl 1():11-3. PubMed ID: 20586499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uses and complications of isotretinoin therapy.
    Ellis CN; Krach KJ
    J Am Acad Dermatol; 2001 Nov; 45(5):S150-7. PubMed ID: 11606947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Déjà vu all over again: skin cap still contains a high-potency glucocorticosteroid.
    Swanson DL; Pittelkow MR; Benson LM; Hawkridge AM; Muddiman DC
    Arch Dermatol; 2005 Jun; 141(6):801-3. PubMed ID: 15967944
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug delivery progress in benign and malignant lesions of aging skin.
    Prow TW; Mandinova A
    Adv Drug Deliv Rev; 2020 Jan; 153():1. PubMed ID: 32867942
    [No Abstract]   [Full Text] [Related]  

  • 32. [New data on the use of dimethylsulfoxide in experimental and clinical dermatology (a survey of the literature)].
    Datskovskii BM; Zaks AS; Mitriukovskii LS
    Vestn Dermatol Venerol; 1973 Jan; 47(1):30-6. PubMed ID: 4575609
    [No Abstract]   [Full Text] [Related]  

  • 33. [The external treatment of dermatoses (author's transl)].
    Ormea F
    MMW Munch Med Wochenschr; 1974 Mar; 116(13):637-42. PubMed ID: 4212846
    [No Abstract]   [Full Text] [Related]  

  • 34. BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis.
    Irrera N; Vaccaro M; Bitto A; Pallio G; Pizzino G; Lentini M; Arcoraci V; Minutoli L; Scuruchi M; Cutroneo G; Anastasi GP; Ettari R; Squadrito F; Altavilla D
    Clin Sci (Lond); 2017 Mar; 131(6):487-498. PubMed ID: 28096316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
    Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
    JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
    [No Abstract]   [Full Text] [Related]  

  • 36. Histopathologic and electron microscopic studies of the effects of Solcoderm on normal epidermis and superficial cutaneous tumors.
    Césarini JP
    Dermatologica; 1984; 168 Suppl 1():15-25. PubMed ID: 6088308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin.
    Johansen C; Flindt E; Kragballe K; Henningsen J; Westergaard M; Kristiansen K; Iversen L
    J Invest Dermatol; 2005 Jun; 124(6):1284-92. PubMed ID: 15955105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [What's new in dermatological treatments?].
    Martin L
    Ann Dermatol Venereol; 2010 Dec; 137 Suppl 4():S165-76. PubMed ID: 21193120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy of biologics with traditional agents in psoriasis.
    Guenther LC
    Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key developments in dermatology.
    Stollery NA
    Practitioner; 2003 Feb; 247(1643):75, 79, 82 passim. PubMed ID: 12621801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.